glycopyrrolate
Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
---|---|---|---|---|---|---|
Seebri Neohaler | CAPSULE, INHALATION | 15.6 mcg | ||||
Lonhala Magnair | SOLUTION, INHALATION | 25 mcg/ mL | ||||
Robinul | SOLUTION, INJECTABLE | 0.2 mg/mL | ||||
Cuvposa | SOLUTION, ORAL | 1 mg/5 mL | ||||
Dartisla | TABLET, DISINTEGRATING, ORAL | 0.85 mg, 1.7 mg | ||||
Robinul | TABLET, ORAL | 1 mg | ||||
Robinul Forte | TABLET, ORAL | 2 mg |
Due to national shortage of the nebulization solutions, the formulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products will automatically return to their original formulary status. See Albuterol/Duoneb Shortage Mitigation for more information. (Updated Feb 2023)
Cuvposa: Formulary status, Restricted to pediatrics. For adults, automatic interchange to hyoscyamine liquid (hyoscyamine 0.125 mg is equivalent to glycopyrrolate 1 mg orally, and proportionately.)
Dartisla ODT: Non-formulary. Recommend alternative therapies for treatment of peptic ulcers (PPIs, H2RAs, Sucralfate). Inpatients may use home supply if alternatives not appropriate. Oral generic glycopyrrolate tablets may also be recommended.
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
glycopyrrolate inhalation (Seebri Neohaler)
ipratropium nebulization
glycopyrrolate inhalation (Lonhala Magnair)
ipratropium nebulization
Reviewed: May 24, 2011 (Cuvposa), and 22 Set 2015 (Cuvposa), and 24 January 2017 (Seebri), and August 2020 (Lonhala Magnair), February 2024 (Dartisla ODT)
Glycopyrrolate (Dartisla ODT)